Clinical trial
Incidence of Cytomegalovirus Infection or Disease Using Valganciclovir Prophylaxis Versus Preemptive Therapy in Intermediate-Risk (R+) Living Donor Kidney Transplant Recipients Receiving Basiliximab-Based Immunosuppression: An Open-Label Clinical Trial (PREVAIL-KT)
NCT07430683 is registered in ClinicalTrials.gov with University of Guadalajara as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Incidence of Cytomegalovirus Infection or Disease Using Valganciclovir Prophylaxis Versus Preemptive Therapy in Intermediate-Risk (R+) Living Donor Kidney Transplant Recipients Receiving Basiliximab-Based Immunosuppression: An Open-Label Clinical Trial (PREVAIL-KT)
- Lead sponsor
- University of Guadalajara
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- March 1, 2024
- Completion date
- July 31, 2026
- Enrollment
- 68 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.